Delayed
Japan Exchange
01:42:58 2025-09-30 am EDT
5-day change
1st Jan Change
4,322.00 JPY
+0.98%
-2.98%
+3.40%
Published on 09/29/2025
at 09:03 pm EDT
Publicnow
Osaka, JAPAN, September 30, 2025 – Takeda (TSE:4502/NYSE:TAK) today reaffirmed its commitment to expand its manufacturing capacity for plasma-derived therapies (PDTs) in Juso, Osaka, and provided an update on project planning as the company continues to respond proactively to changing market conditions.
Since announcing the project in March 2023, Takeda, together with a leading general contractor as its prospective partner, has made considerable progress working through the phases of conceptual, basic, and detailed design in line with disclosed plans. Informed by factors such as the depreciation of the yen, substantial rises in construction material costs, and ongoing labor shortages in the construction sector in Japan, Takeda reported in its Semi-annual Securities Report and Annual Securities Report of fiscal year 2024 an upward revision of the total investment to 153 billion yen, with an updated construction start in fiscal year 2025 and targeted completion in fiscal year 2029.
Following a recent comprehensive review of construction costs with our partners, Takeda has observed additional upward pressures on project costs. To ensure that our investment delivers enduring benefits for patients and the healthcare system in Japan and worldwide, Takeda will reevaluate the scope of the construction plan, as well as the timeline for both the commencement and the completion of the construction.
Takeda remains fully committed to people who rely on plasma-derived therapies. This reevaluation is part of our responsibility to enable the long-term success and sustainability of this investment. Our intent is to strengthen plans to ensure a robust and stable supply of these vital treatments to all patients in Japan and worldwide, contributing to better health and a brighter future for people around the world.
We will provide further updates as appropriate, in a timely and suitable manner should there be any relevant developments.
**Osaka, JAPAN, September 30, 2025** – Takeda ([TSE:4502/NYSE:TAK](/investors/overview/)) today reaffirmed its commitment to expand its manufacturing capacity for plasma-derived therapies (PDTs) in Juso, Osaka, and provided an update on project planning as the company continues to respond proactively to changing market conditions. Since announcing the project in March 2023, Takeda, together with a leading general contractor as its prospective partner, has made considerable progress working through the phases of conceptual, basic, and detailed design in line with disclosed plans. Informed by factors such as the depreciation of the yen, substantial rises in construction material costs, and ongoing labor shortages in the construction sector in Japan, Takeda reported in its [Semi-annual Securities Report](https://assets-dam.takeda.com/image/upload/v1730341347/Global/Investor/ASR/FY2024/asr148_q2_en.pdf) and [Annual Securities Report](https://assets-dam.takeda.com/image/upload/v1750813404/Global/Investor/ASR/E_FY24_ASR.pdf) of fiscal year 2024 an upward revision of the total investment to 153 billion yen, with an updated construction start in fiscal year 2025 and targeted completion in fiscal year 2029. Following a recent comprehensive review of construction costs with our partners, Takeda has observed additional upward pressures on project costs. To ensure that our investment delivers enduring benefits for patients and the healthcare system in Japan and worldwide, Takeda will reevaluate the scope of the construction plan, as well as the timeline for both the commencement and the completion of the construction. Takeda remains fully committed to people who rely on plasma-derived therapies. This reevaluation is part of our responsibility to enable the long-term success and sustainability of this investment. Our intent is to strengthen plans to ensure a robust and stable supply of these vital treatments to all patients in Japan and worldwide, contributing to better health and a brighter future for people around the world. We will provide further updates as appropriate, in a timely and suitable manner should there be any relevant developments.
Attachments
Original documentPermalink
Disclaimer
Takeda Pharmaceutical Co. Ltd. published this content on September 30, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 30, 2025 at 01:02 UTC.
Takeda Pharmaceutical: Update on construction of new plasma-derived therapies manufacturing facility in Juso, Osaka
11:52pm
RE
Alkermes’ Stock Dip on Narcolepsy Data Seen as Buying Opportunity, RBC Says
Sep. 26
MT
Japan’s Topix posts record-high close despite US tariffs on pharma
Sep. 26
RE
Japan’s Topix hits record high despite US tariffs on pharma
Sep. 25
RE
Japanese Shares End Slightly Higher As Weak Yen Boosts Exporters
Sep. 25
MT
Takeda Reclassifies 834 Billion Yen in Reserves to Retained Earnings
Sep. 24
MT
Japanese Shares Slip As Investors Await Fed Rate Cut, Japan Exports Extend Decline
Sep. 17
MT
Takeda Uses AI To Forecast Drug Demand, Cut Waste
Sep. 17
MT
Takeda and VELA to Ship Medicines Across the Atlantic Using First-Of-Its-Kind Wind-Powered Trimaran
Sep. 16
CI
Takeda appoints Rhonda Pacheco president of the U.S. business unit
Sep. 11
RE
Takeda Announces Executive Changes, Effective June 2026
Sep. 11
CI
Takeda Announces Executive Changes, Effective September 29
Sep. 11
CI
Nikkei ends lower on yen strength, profit-taking after crossing 44,000
Sep. 09
RE
Takeda Pharmaceutical Company Limited Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-08-2025 03:20 PM
Sep. 09
Takeda Pharmaceutical Company Limited – Special Call
Sep. 08
Takeda Presents Orexin Data from Landmark Oveporexton Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
Sep. 08
CI
Takeda Gets FDA Approval for Expanded Label for Bleeding Disorder Therapy
Sep. 08
MT
Takeda Pharmaceutical Reports Positive Phase 3 Results for Oveporexton in Narcolepsy Type 1
Sep. 08
MT
Takeda presents orexin data from landmark oveporexton (TAK-861) phase 3 program in narcolepsy type 1 at World Sleep 2025
Sep. 08
RE
Takeda Announces U.S. FDA Approves Expanded Indication for VONVENDI for Adults and Children with Von Willebrand Disease
Sep. 06
CI
Novavax Says COVID-19 Vaccine Approval in Japan Triggers Takeda Milestone Payment
Sep. 04
MT
Takeda Pharmaceutical Says Fruzaqla Included in Reimbursable Medicines in Quebec, Canada
Aug. 28
MT
Protagonist Therapeutics Says Rusfertide Gets US FDA Breakthrough Therapy Designation for Blood Condition Treatment
Aug. 25
MT
US FDA approves Ionis’ drug for rare genetic disorder
Aug. 21
RE
Veeva Systems Q2 Results Likely In-Line to Better, Maintain H2 Outlook, Truist Says
Aug. 20
MT
DurationAuto.2 months3 months6 months9 months1 year2 years5 years10 yearsMax.
PeriodDayWeek
4502: Dynamic Chart
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company’s research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
More about the company
Sell
Buy
Last Close Price
4,280.00JPY
Average target price
5,009.12JPY
Spread / Average Target
+17.04%
Consensus
Stock MarketStock Market NewsTakeda Pharmaceutical : Update on Construction of New Plasma-Derived Therapies Manufacturing Facility in Juso, Osaka
OUR EXPERTS ARE HERE FOR YOU
Monday – Friday 9am-12pm / 2pm-6pm GMT + 1
Select your edition
All financial news and data tailored to specific country editions
AloJapan.com